KBC Group’s Acadia Pharmaceuticals ACAD Stock Holding History

KBC Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$81K	Hold	3,619	–	–	﹤0.01%	1444
2025 Q4	$97K	Hold	3,619	–	–	﹤0.01%	1300
2025 Q3	$77K	Hold	3,619	–	–	﹤0.01%	1422
2025 Q2	$78K	Sell	3,619 -1,474	-29%	-$27.4K	﹤0.01%	1360
2025 Q1	$85K	Hold	5,093	–	–	﹤0.01%	1574
2024 Q4	$93K	Buy	5,093 +2,044	+67%	+$33K	﹤0.01%	1602
2024 Q3	$47K	Hold	3,049	–	–	﹤0.01%	1733
2024 Q2	$50K	Buy	+3,049	New	+$49.2K	﹤0.01%	1609
2024 Q1	–	Sell	-2,659	Closed	-$83K	–	1845
2023 Q4	$83K	Hold	2,659	–	–	﹤0.01%	1162
2023 Q3	$55K	Buy	+2,659	New	+$72.2K	﹤0.01%	1364

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

KBC Group's ACAD Position: Q1 2026 in Review

KBC Group held its Acadia Pharmaceuticals (ACAD) position steady in Q1 2026 at 3,619 shares worth $81K. The position accounts for ﹤0.01% of the portfolio, ranked #1444.

KBC Group first reported a position in ACAD in Q3 2023 and has held it in 10 quarters since. The position peaked at $97K in Q4 2025. 341 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

KBC Group held 3,619 shares of Acadia Pharmaceuticals worth $81K as of Q1 2026.
KBC Group left its Acadia Pharmaceuticals share count unchanged in Q1 2026.
Acadia Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1444 holding.
KBC Group first reported a position in Acadia Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
KBC Group's Acadia Pharmaceuticals position peaked at $97K in Q4 2025.
341 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.